Evaluation of menogaril in renal cell carcinoma - A Southwest Oncology Group phase II study (8504)

Ronald L. Stephens; Phyllis Goodman; E. David Crawford; Connie F. Spicer; Bruce A. Lowe; Frederick R. Ahmann; Robert Chapman; Ronald B. Natale

doi:10.1007/BF00171987

Evaluation of menogaril in renal cell carcinoma - A Southwest Oncology Group phase II study (8504)

Ronald L. Stephens, Phyllis Goodman, E. David Crawford, Connie F. Spicer, Bruce A. Lowe, Frederick R. Ahmann, Robert Chapman, Ronald B. Natale

Cancer Center

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m² i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer.

Original language	English (US)
Pages (from-to)	S69-S71
Journal	Investigational New Drugs
Volume	8
Issue number	1 Supplement
DOIs	https://doi.org/10.1007/BF00171987
State	Published - Mar 1990

Keywords

menogaril
renal cell carcinoma

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00171987

Cite this

@article{17398c3bc11e4f9195916df45cd98daa,

title = "Evaluation of menogaril in renal cell carcinoma - A Southwest Oncology Group phase II study (8504)",

abstract = "The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer.",

keywords = "menogaril, renal cell carcinoma",

author = "Stephens, {Ronald L.} and Phyllis Goodman and Crawford, {E. David} and Spicer, {Connie F.} and Lowe, {Bruce A.} and Ahmann, {Frederick R.} and Robert Chapman and Natale, {Ronald B.}",

year = "1990",

month = mar,

doi = "10.1007/BF00171987",

language = "English (US)",

volume = "8",

pages = "S69--S71",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "1 Supplement",

}

TY - JOUR

T1 - Evaluation of menogaril in renal cell carcinoma - A Southwest Oncology Group phase II study (8504)

AU - Stephens, Ronald L.

AU - Goodman, Phyllis

AU - Crawford, E. David

AU - Spicer, Connie F.

AU - Lowe, Bruce A.

AU - Ahmann, Frederick R.

AU - Chapman, Robert

AU - Natale, Ronald B.

PY - 1990/3

Y1 - 1990/3

N2 - The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer.

AB - The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer.

KW - menogaril

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0025344876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025344876&partnerID=8YFLogxK

U2 - 10.1007/BF00171987

DO - 10.1007/BF00171987

M3 - Article

C2 - 2143177

AN - SCOPUS:0025344876

SN - 0167-6997

VL - 8

SP - S69-S71

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1 Supplement

ER -

Evaluation of menogaril in renal cell carcinoma - A Southwest Oncology Group phase II study (8504)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this